Duarte Machado, oncologista do Hospital do Divino Espírito Santo de Ponta Delgada, Açores, comenta o estudo “A randomized, double-blind, placebo-controlled phase II study of adjuvant pembrolizumab versus placebo in patients with head and neck squamous cell cancers at high risk for recurrence: The PATHWay study”.